(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

PHASE2CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

November 21, 2018

Primary Completion Date

December 18, 2024

Study Completion Date

December 18, 2024

Conditions
Advanced Systemic MastocytosisAggressive Systemic MastocytosisSystemic Mastocytosis With an Associated Hematologic NeoplasmMast Cell Leukemia
Interventions
DRUG

Avapritinib

Avapritinib tablet

Trial Locations (32)

1090

Medizinische Universität Wien, Universitätsklinik für Innere Medizin I, Klinische Abteilung für Hämatologie und Hämostaseologie, Vienna

10032

Herbert Irving Comprehensive Cancer Center, New York

14263

Roswell Park Comprehensive Cancer Center, Buffalo

19104

University of Pennsylvania, Abramson Cancer Center, Philadelphia

20246

Universitätsklinikum Hamburg-Eppendorf, Zentrum für Onkologie, Hamburg

31059

CHU Toulouse - Hôpital Larrey, Toulouse

37134

Centro Ricerche Cliniche di Verona - Azienda Ospedaliera Universitaria Integrata di Verona, Verona

45071

lnstituto de Estudios de Mastocitosis de Castilla la Mancha, Hospital Virgen del Valle - Complejo Hospitalario de Toledo, Toledo

48109

University of Michigan, Ann Arbor

50134

Azienda Ospedaliero-Universitaria Careggi, CRIMM - Centro di Ricerca ed Innovazione per le Malattie Mieloproliferative, Florence

52074

Uniklinik RWTH Aachen, Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltranslplantation, Aachen

60612

Rush University Medical Center, Chicago

63110

Washington University School of Medicine, St Louis

66205

The University of Kansas Cancer Center, Westwood

68167

Universitätsmedizin Mannheim III. Medizinische Klinik, Mannheim

75015

Hôpital Necker-Enfants Malades, Paris

77030

University of Texas, MD Anderson Cancer Center, Houston

78229

Mays Cancer Center, San Antonio

81675

Klinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar der TU München, Munich

84112

Huntsman Cancer Institute, Salt Lake City

84131

A.O. OO.RR. S.Giovanni di Dio e Ruggi d'Aragona, University of Salerno, Salerno

94305

Stanford Cancer Institute, Stanford

02215

Dana Farber Cancer Institute, Boston

M5B 1W8

St. Michael's Hospital, Toronto

DK-5000

Odense University Hospital, Department of Haematology, Odense

04103

Universitätsklinikum Leipzig, Medizinische Klinik und Poliklinik I - Hämatologie und Zelltherapie, lnternistische Onkologie, Hämostaseologie, Leipzig

9713 GZ

University Medical Center Groningen (UMCG), Groningen

0372

Oslo University Hospital-Rikshospitalet, Hematology, Oslo

80-214

Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii, Gdansk

50-367

Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu, Klinice Hematologii, Nowotworów Krwi i Transplantacji Szpiku, Wroclaw

G12 0YN

Beatson West of Scotland Cancer Centre - NHS Greater Glasgow and Clyde, Glasgow

SE1 9RT

Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital, London

All Listed Sponsors
lead

Blueprint Medicines Corporation

INDUSTRY